doc6th European Post-Chicago Melanoma/Skin Cancer Meeting
download 
Report Transcription
6th European Post-Chicago Melanoma/Skin Cancer Meeting
Congress Presidents Axel Hauschild, Kiel, Germany Claus Garbe, Tuebingen, Germany Final Program (updated: 23/03/16) 6 th European Post-Chicago Melanoma/Skin Cancer Meeting Results and Interpretations of ASCO Presentations 2016: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer June 30 th– July 1st, 2016 Munich, Germany Leonardo Royal Hotel www.melanomaglobal2016.org Under the auspices of the European Association of Dermato-Oncology CONTENT WELCOME MESSAGE 01 PROGRAM AT A GLANCE 02 PROGRAM 04 Thursday, June 30th 04 Friday, July 1st 07 CONGRESS FACULTY 10 FLOOR PLAN 13 SATELLITE SYMPOSIA OVERVIEW 14 GENERAL INFORMATION 17 SPONSORS 20 REGISTRATION FORM 21 WELCOME MESSAGE Dear colleagues and friends, Since the first Post-Chicago Meeting on Melanoma/Skin Cancer took place in 2011, it has attracted up to 580 participants each year from all over the world. The interactive congress offers a comprehensive overview on all new developments in melanoma diagnostics and therapy and a direct communication with the world´s leading experts in these fields. Presently, there are many new developments in melanoma diagnostics and treatment. New devices may enable a more precise diagnostics of primary melanoma and allow earlier detection. For metastatic melanoma, there is a rapid change of therapeutic approaches. New drugs like BRAF- and MEK-inhibitors and CTLA4 and PD1-antibodies are already established in melanoma treatment. However, it remains an open question how to combine them and how they should be sequentially applied. Additionally, the significance of other drugs and vaccines like T-VEC has still to be determined. Nevertheless, it will be the main target for all of us to choose the right patients for the right drugs! The aim of the Interdisciplinary Global Conference on Developing New Treatments for Melanoma/Skin Cancer in Munich is to grant a deep overall insight into the development of new drugs for melanoma and other cutaneous malignancies. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant. International key opinion leaders on melanoma will be invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of Germany. Please join us for this event and submit your own studies and case presentations as free communications and as posters. We look forward to welcoming you in Munich in June 2016! Axel Hauschild, MD Congress President Claus Garbe, MD Congress President 1 PROGRAM AT A GLANCE THURSDAY, JUNE 30TH ROYAL BALLROOM R1+R2 8:00 9:00 Opening of the conference SYMPOSIUM I My personal highlights at ASCO 2016 10:00 11:00 KEY NOTE LECTURE COFFEE BREAK 12:00 SATELLITE SYMPOSIUM I with lunch (platinum sponsor) 13:00 SYMPOSIUM II Adjuvant treatment of melanoma PARALLEL SESSION I Prognostic and predictive markers for tumor response 14:00 COFFEE BREAK 15:00 SATELLITE SYMPOSIUM II (platinum sponsor) 16:00 SYMPOSIUM III Current Clinical Trials I 17:00 18:00 SYMPOSIUM IV Frequent and rare adverse events of new drugs SYMPOSIUM 2 SATELLITE SYMPOSIUM KEY NOTE LECTURE PARALLEL SESSION FREE COMMUNICATIONS FRIDAY, JULY 1ST ROYAL BALLROOM 8:00 R1+R2 POSTER VIEWING & POSTER AWARD KEY NOTE LECTURE 9:00 SATELLITE SYMPOSIUM III (platinum sponsor) 10:00 COFFEE BREAK SATELLITE SYMPOSIUM IV (platinum sponsor) 11:00 COFFEE BREAK 12:00 SATELLITE SYMPOSIUM V with lunch (platinum sponsor) 13:00 SYMPOSIUM V Current Clinical Trials II 14:00 15:00 PARALLEL SESSION II EADO Forum: Our most interesting melanoma cases COFFEE BREAK SATELLITE SYMPOSIUM VI (platinum sponsor) 16:00 17:00 SYMPOSIUM VI Standard of care for BRAF mutated melanoma? Pros and Cons FREE COMMUNICATIONS 18:00 CLOSING REMARKS 3 THURSDAY, JUNE 30TH 09:30 OPENING OF THE CONFERENCE ROYAL BALLROOM CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY EADO presidential address 09:40 –11:00 SYMPOSIUM I ROYAL BALLROOM My personal highlights at ASCO 2016 CHAIRPERSONS: SANJIV AGARWALA, BETHLEHEM, USA CAROLA BERKING, MUNICH, GERMANY 09:40–10:00 10:05–10:25 10:30–10:50 … in immunotherapy Michael A. Postow, New York, USA … in targeted therapies Olivier Michielin, Lausanne, Switzerland … in non melanoma skin cancer Celeste Lebbé, Paris, France 11:00 –11:30 KEY NOTE LECTURE ROYAL BALLROOM CHAIRPERSON: ROLAND KAUFMANN, FRANKFURT, GERMANY 11:00-11:30 Mutational testing in melanoma Grant McArthur, Melbourne, Australia 11:30 –12:00 COFFEE BREAK 12:00 –13:30 SATELLITE SYMPOSIUM I with lunch ROYAL BALLROOM (platinum sponsor) (see page 14) 4 THURSDAY, JUNE 30TH 13:30 –14:30 SYMPOSIUM II Adjuvant treatment of melanoma ROYAL BALLROOM CHAIRPERSONS: HUBERT PEHAMBERGER, VIENNA, AUSTRIA JOHN KIRKWOOD, PITTSBURGH, USA 13:30 –13:42 Interferons – still worthwhile? John Kirkwood, Pittsburgh, USA 13:45 –13:57Checkpoint inhibitors Paolo Ascierto, Naples, Italy 14:00 –14:12Targeted therapies Thomas Eigentler, Tuebingen, Germany 14:15 –14:27Neoadjuvant treatment Dirk Schadendorf, Essen, Germany 13:30–14:30PARALLEL SESSION I R1+R2 Prognostic and predictive markers for tumor response CHAIRPERSONS:STEPHAN GRABBE, MAINZ, GERMANY MICHELE MAIO, SIENA, ITALY 13:30–13:46 13:50–14:06 14:10–14:26 Prognostic markers in melanoma Michele Maio, Sienna, Italy Predictive markers for checkpoint inhibition Benjamin Weide, Tuebingen, Germany Predictive markers for targeted therapies Jennifer Landsberg, Bonn, Germany 14:30 –15:00 COFFEE BREAK 15:00 –16:30 SATELLITE SYMPOSIUM II ROYAL BALLROOM (platinum sponsor) (see page 14) 5 THURSDAY, JUNE 30TH 16:30 –17:50 SYMPOSIUM III Current Clinical Trials I ROYAL BALLROOM CHAIRPERSONS: KATHARINA KÄHLER, KIEL, GERMANY PETER MOHR, BUXTEHUDE, GERMANY 16:30–16:45 16:50–17:05 17:10–17:25 17:30–17:45 Ocular Melanoma Bastian Schilling, Essen, Germany Mucosal Melanoma Carola Berking, Munich, Germany Brain Metastases Friedegund Meier, Dresden, Germany Soft Tissue/Skin Metastases Sanjiv Agarwala, Bethlehem, USA 18:00 –19:00 SYMPOSIUM IV ROYAL BALLROOM Frequent and rare adverse events of new drugs CHAIRPERSONS: CAROLINE ROBERT, PARIS, FRANCE RALF GUTZMER, HANNOVER, GERMANY 18:00–18:10 18:15–18:25 18:30–18:40 18:45–18:55 6 Immune checkpoint inhibitors: Frequent AEs Caroline Robert, Paris, France Immune checkpoint inhibitors: Rare AEs Lucie Heinzerling, Erlangen, Germany Targeted therapies: Frequent AEs Elisabeth Livingstone, Essen, Germany Targeted therapies: Rare AEs Celeste Lebbé, Paris, France FRIDAY, JULY 1ST 08:00 –08:30 POSTER VIEWING & POSTER AWARD ROYAL BALLROOM POSTER GUIDES:RALF GUTZMER, HANNOVER, GERMANY SELMA UGUREL, ESSEN, GERMANY 08:30 –09:30KEY NOTE LECTURE ROYAL BALLROOM CHAIRPERSONS: C LAUS GARBE, TUEBINGEN, GERMANY JOHN KIRKWOOD, PITTSBURGH, USA 08:30– 09:00 09:00– 09:30 How does immune checkpoint inhibition work? Antoni Ribas, Los Angeles, USA Is cure of metastatic melanoma on the horizon? Caroline Robert, Paris, France 09:30–10:00 SATELLITE SYMPOSIUM III ROYAL BALLROOM (platinum sponsor) (see page 14) 10:00 –10:30 COFFEE BREAK 10:30 –11:30 SATELLITE SYMPOSIUM IV ROYAL BALLROOM (platinum sponsor) (see page 14) 11:30 –12:00 COFFEE BREAK 7 FRIDAY, JULY 1ST 12:00 –13:30 SATELLITE SYMPOSIUM V with lunch ROYAL BALLROOM (platinum sponsor) (see page 14) 13:30 –14:50 SYMPOSIUM V Current Clinical Trials II ROYAL BALLROOM CHAIRPERSONS: CHRISTIAN BLANK, AMSTERDAM, NETHERLANDS CHRISTOPH HÖLLER, VIENNA, AUSTRIA 13:30-13:42 13:46–13:58 14:02–14:14 14:18–14:30 14:34–14:46 MAGE-A3 vaccination (DERMA-trial): Final results Brigitte Dréno, Nantes, France BRAF + MEK inhibition James Larkin, London, United Kingdom NEMO trial: Binimetinib for NRAS-mutated melanoma Reinhard Dummer, Zurich, Switzerland Combined immune checkpoint inhibition Christian Blank, Amsterdam, Netherlands Chemosaturation in liver metastasis Roland Kaufmann, Frankfurt, Germany 13:30–15:00 PARALLEL SESSION II EADO Forum: Our most interesting melanoma cases R1+R2 CHAIRPERSONS:KETTY PERIS, ROME, ITALY IRIS ZALAUDEK, GRAZ, AUSTRIA 13:30–13:37 13:40–13:47 13:50–13:57 14:00–14:07 14:10–14:17 14:20–14:27 14:30–14:37 14:40–14:47 8 Case 1 Josef Malvehy, Barcelona, Spain Case 2 Matilda Bylaitė Bučinskienė, Vilnius, Lithuania Case 3 Ana Maria Forsea, Bucharest, Romania Case 4 Ketty Peris, Rome, Italy Case 5 Lidija Kandolf-Sekulovic, Belgrade, Serbia Case 6 Judith Oláh, Szeged, Hungary Case 7 Iris Zalaudek, Graz, Austria Case 8 Petr Arenberger, Prague, Czech Republic FRIDAY, JULY 1ST 15:00 –15:30 COFFEE BREAK 15:30 –17:00 SATELLITE SYMPOSIUM VI ROYAL BALLROOM (platinum sponsor) (see page 14) 17:00 –18:25 SYMPOSIUM VI Standard of care for BRAF mutated melanoma? Pros and Cons ROYAL BALLROOM CHAIRPERSONS: SELMA UGUREL, ESSEN, GERMANY AXEL HAUSCHILD, KIEL, GERMANY 17:00 –17:25 17:30 –17:55 18:00 –18:25 My first choice: Immunotherapy Antoni Ribas, Los Angeles, USA My first choice: BRAF + MEK inhibition Dirk Schadendorf, Essen, Germany Round Table Discussion Australian View: Grant McArthur European View: Reinhard Dummer / Dirk Schadendorf US View: Sanjiv Agarwala / Antoni Ribas 17:00 –18:20 FREE COMMUNICATIONS R1+R2 CHAIRPERSONS: JESSICA HASSEL, HEIDELBERG, GERMANY JENNIFER LANDSBERG, BONN, GERMANY 18:25 –18:30 CLOSING REMARKS ROYAL BALLROOM Claus Garbe, Tuebingen, Germany 9 CONGRESS FACULTY A Sanjiv S. Agarwala , MD Professor of Medicine St. Lukes Cancer Center, Temple University 2145 Augusta DR Center Valley PA 18034 USA Phone: +1-610-297-0169 Email: [email protected] Robert Andtbacka, MD Associate Professor of Surgical Oncology Department of Surgery University of Utah Huntsman Cancer Institute 2000 Circle of Hope Drive Salt Lake City, Utah 84112-5550 USA Phone: +1 801 587 8808 Email: [email protected] Petr Arenberger, MD Department of Dermatology, Charles University, 3rd School of Medicine Srobarova 50 CZ-100 34 Prague Czech Republic Phone: +420-26716-3000 Email: [email protected] Paolo A. Ascierto, MD Melanoma, Cancer Immunotherapy and Innovative Therapy Unit Istituto Nazionale Tumori Fondazione “G. Pascale” Via Mariano Semmola 80131 Naples Italy Phone: +39-081-5903236 Email: [email protected] B Carola Berking, MD Professor of Dermatology Department of Dermatology and Allergology University Hospital Munich (LMU) Frauenlobstr. 9–11 80337 Munich Germany Phone: +49-89-4400-56225 Email: [email protected] Christian Blank, MD The Netherlands Cancer Institute Plesmanlaan 121 1066 CX Amsterdam The Netherlands Phone: +31-20-512-2570 Email: [email protected] 10 Matilda Bylaite-Bucinskiene, MD Professor of Dermatology Chairwoman of the Centre of Dermatovenereology President of Lithuanian Association of Dermatovenereologists Vilnius University Hospital Santariskiu Klinikos Kairiukscio str. 2 08411 Vilnius Lituania Phone: +370-5-2720385 Email: [email protected] D Brigitte Dréno, MD Professor of Dermatology Chairman of the department of Dermatology, Director of the Unit of gene and Cell Therapy, Vice Dean for Research at the Faculty of Medicine Nantes France CHU Nantes Place Alexis Ricordeau 44093 Cedex 01 France Phone: +33-2-40083118 Email: [email protected] Reinhard Dummer, MD Professor of Dermatology Department of Dermatology Vice Chairman, University of Zurich Hospital Gloriastrasse 31 8091 Zurich Switzerland Phone: +41-442552507 Email: [email protected] E Thomas Eigentler, MD Department of Dermatology Eberhard Karls University Liebermeister Str. 25 72076 Tuebingen Germany Phone: +49-7071-2985748 Email: thomas.eigentler@ med.uni-tuebingen.de F Ana Maria Forsea, MD Assistant Professor for Dermatology Department of Dermatology Carol Davila University of Medicine and Pharmacy Bucharest Bulevardul Eroii Sanitari 8 Bucharest 050474 Romania Phone: +40-21-3180462 Email: [email protected] G Claus Garbe, MD Professor of Dermatology Department of Dermatology Eberhard Karls University Liebermeister Str. 25 72076 Tuebingen Germany Phone: +49-7071-2987110 Email: [email protected] Stephan Grabbe, MD Professor of Dermatology, Director Department of Dermatology Johannes Gutenberg University Langenbeckstr. 1 55131 Mainz Germany Phone: +49-6131-172910 Email: [email protected] Ralf Gutzmer, MD Professor of Dermatology Skin Cancer Center, Department of Dermatology Hannover Medical School Carl-Neuberg-Str. 1 30625 Hannover Germany Phone: +49-511-532-0 Email: [email protected] H Jessica Hassel, MD Department of Dermatology, University Hospital Heidelberg and Nationales Centrum für Tumor erkrankungen (NCT) Im Neuenheimer Feld 460 69120 Heidelberg Germany Phone: +49-6221-5638503 Email: [email protected] Axel Hauschild, MD Professor of Dermatology Department of Dermatology University of Kiel Schittenhelmstr. 7 24105 Kiel Germany Phone: +49-431-5971852 Email: [email protected] Lucie Heinzerling, MD, PhD, MPH Professor Department of Dermatology University Hospital of Erlangen Ulmenweg 18 91054 Erlangen Germany Phone: +49-9131-8539037 Email: [email protected] Christoph Höller, MD Professor of Dermatology Department of Dermatology Medical University of Vienna Waehringer Gürtel 18-20 1090 Vienna Austria Phone: +43-1-404004786 Email: [email protected] K Katharina Kähler, MD Department of Dermatology University of Kiel Schittenhelmstr. 7 24105 Kiel Germany Phone: +49-431-5971512 Email: [email protected] Lidija Kandolf-Sekulovic, MD Department of Dermatology Military Medical Academy Crnotravska 17 11000 Belgrade Serbia Phone: +381-113608583 Email: [email protected] Roland Kaufmann, MD Professor of Dermatology, Director Department of Dermatology Clinical Center J. W. Goethe University Theodor-Stern-Kai 7 60590 Frankfurt am Main Germany Phone: +49-69-63015311 Email: [email protected] John Kirkwood, MD Usher Professor of Medicine, Dermatology and Translational Science Director Melanoma and Skin Cancer Program University of Pittsburgh Hillman Cancer Center Laboratory Suite L1.32c 5117 Centre Avenue, Suite 1.32 Pittsburgh PA 15213 USA Phone: 001-412-623-7707 Email: [email protected] L Jennifer Landsberg, MD Department of Dermatology University of Bonn Sigmund-Freud-Straße 25 53127 Bonn Germany Phone: +49-228-73-7021 Email: [email protected] Josep Malvehy, MD Director of the Melanoma Unit Department of Dermatology Hospital Clinic of Barcelona C/Villarroel 170 08036 Barcelona Spain Phone: +34-933638920 Email: [email protected] Grant McArthur, MD Professor of Medicine Head Cancer Therapeutics Program Head Skin and Melanoma Service Divisions of Cancer Medicine and Research Peter MacCallum Cancer Centre Locked Bag 1A’Beckett St Melbourne 8006 Australia Phone: +61-3-9656-3649 Email: [email protected] James Larkin, MD Consultant Medical Oncologist The Royal Marsden Hospital Fulham Road London, SW3 6JJ United Kingdom Phone: +44-207-8118576 Email: [email protected] Friedegund Meier, MD Professor of Dermatooncology Department of Dermatology University Hospital Carl Gustav Carus Technical University Dresden Fetscherstr. 74 01307 Dresden Germany Phone: +49-351-4583677 Email: [email protected] Celeste Lebbé, MD Professor of Dermatology Department of Dermatology Hôpital Saint-Louis 1, Avenue Claude-Vellefaux 75010 Paris France Phone: +33-142494679 Email: [email protected] Olivier Michielin, MD Professor Swiss Institute of Bioinformatics Molecular Modeling Group Quartier Sorge - Batiment Genopode CH-1015 Lausanne Switzerland Phone: +41-21-692-4053 Email: [email protected] Elisabeth Livingstone, MD University Hospital Essen Hauttumorzentrum Hufelandstr. 55 45122 Essen Germany Phone: +49-201-7232431 Email: [email protected] Peter Mohr, MD Center of Dermatology Elbe Klinikum Buxtehude Am Krankenhaus 1 21614 Buxtehude Germany Phone: +49-41617036209/-6250 Email: [email protected] M O Michele Maio, MD Professor of Oncology Department of Medical Oncology and Immunotherapy University Hospital of Siena Strada della Scotte no. 14 53100 Siena Italy Phone: +39-0577586336 Email: [email protected] Judit Oláh, MD Department of Dermatology University of Szeged Koranyi Fasor 6 3720 Szeged Hungary Phone: +36-62-545984 Email: [email protected] 11 P S Hubert Pehamberger, MD Professor and Chairman Department of Dermatology Medical University of Vienna Waehringer Guertel 18-20 1090 Vienna Austria Phone: +43-1-404007710 Email: hubert.pehamberger@ meduniwien.ac.at Dirk Schadendorf, MD Professor of Dermatology Department of Dermatology University Hospital Essen Hufelanstr. 55 45147 Essen Germany Phone: +49-201-7232430 Email: [email protected] Ketty Peris, MD Department of Dermatology Catholic University of Rome Largo a Gemelli, 8 00168 Rome Italy Phone: +39-630154227 Email: [email protected] Michael A. Postow, MD Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065 USA Phone: +1-646-888-4589 Email: [email protected] Paola Queirolo, MD Presidente IMI UOC Oncologia Medica IRCCS San Martino-IST Genova Italy Email: [email protected] R Antoni Ribas, MD Professor of Medicine, Surgery and Molecular and Medical Pharmacology University of California Los Angeles UCLA Medical Center Hematology/ Oncology 100 UCLA Medical Plaza, Suite 550 Los Angeles, 90095 USA Phone: +1-310-794-4955 Email: [email protected] Caroline Robert MD, PhD Head Dermatology Gustave Roussy Institute 114 rue Edouard Vaillant 94801 Villejuif France Phone: +33-1-4211-64-97 Email: [email protected] 12 Bastian Schilling, MD Department of Dermatology University Hospital Essen Hufelandstraße 55 45147 Essen Germany Phone: +49-201-723-83590 Email: [email protected] U Selma Ugurel, MD Professor of Dermatology Department of Dermatology University Hospital Essen Hufelandstr. 55 45122 Essen Germany Phone: +49-201-7234714 Email: [email protected] W Benjamin Weide, MD Department of Dermatology Eberhard Karls University Liebermeister Str. 25 72076 Tuebingen Germany Phone: +49-7071-2984555 Email: benjamin.weide@ med.uni-tuebingen.de Z Iris Zalaudek, MD Division of Dermatology and Venerology Non-Melanoma Skin Cancer Unit Medical University of Graz Auenbruggerplatz 8 8036 Graz Austria Phone: +43-6763328269 Email: [email protected] ERDGESCHOSS/GROUND FLOOR Terrasse/terrace R7 R6 R5 SpeakerPreviewRoom R3 künstlicher Wasserlauf/ artificial water point R4 Service R2 R1 Business Center Davidoff Lounge Lobby Lifts Registration Desk WC/ toilet Moosacher Straße 90 Reception Desk Einfahrt Tiefgarage/ access underground parking Foyer Service Terrasse/terrace Back Office Hoteleingang/ hotel entrance UNTERGESCHOSS/BASEMENT LEONARDO ROYAL HOTEL MUNICH FLOOR PLAN 13 SATELLITE SYMPOSIA OVERVIEW THURSDAY, JUNE 30TH 2:00 –13:30 SATELLITE SYMPOSIUM I with lunch 1 Amgen (platinum sponsor) ROYAL BALLROOM Unlocking antigens to ignite tumor immunity in melanoma CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY 12:00–12:10Where we are now with melanoma treatment Axel Hauschild, Kiel, Germany 12:10–12:45Oncolytic immunotherapy: from concept to clinical trials Josep Malvehy, Barcelona, Spain Robert Andtbacka, Salt Lake City, USA 12:45–13:20Practical considerations when using talimogene laherparepvec Josep Malvehy, Barcelona, Spain Robert Andtbacka, Salt Lake City, USA 13:20–13:30Future perspectives for melanoma and beyond Axel Hauschild, Kiel, Germany 5:00 –16:30 SATELLITE SYMPOSIUM II 1 Bristol-Myers Squibb (platinum sponsor) ROYAL BALLROOM The I-O approach in advanced melanoma – from mono- to combination-therapy CHAIRPERSON: CLAUS GARBE, TUEBINGEN, GERMANY 15:00–15:30Checkpoint modifiers in advanced melanoma – from mono- to combination-therapy James Larkin, London, United Kingdom 15:30–16:00Therapy of patients with advanced melanoma – an individual approach Peter Mohr, Buxtehude, Germany 16:00–16:30Panel discussion & Final discussion Claus Garbe, Tuebingen, Germany James Larkin, London, United Kingdom Peter Mohr, Buxtehude, Germany and the audience 14 FRIDAY, JULY 1ST 9:30 –11:30 SATELLITE SYMPOSIUM III and IV 0 Roche (platinum sponsor) ROYAL BALLROOM Your opinion matters – An interactive panel discussion on: Hot topics of targeted therapies in BCC and melanoma CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY 09:30–10:00 A re there new therapeutic approaches for hedgehoc inhibitors in BCC? Ralf Gutzmer, Hannover, Germany 10:00–10:30 Coffee Break 10:30–11:30The future of targeted therapies in melanoma? Olivier Michielin, Lausanne, Switzerland Reinhard Dummer, Zurich, Switzerland Carola Berking, Munich, Germany Grant McArthur, Melbourne, Australia Christian Blank, Amsterdam, The Netherlands 2:00 –13:30 SATELLITE SYMPOSIUM V with lunch 1 Merck/MSD (platinum sponsor) ROYAL BALLROOM Integrating immuno-oncology therapies into clinical practice: An expert discussion CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY 12:00–12:05 W elcome and Introduction Axel Hauschild, Kiel, Germany 12:05–12:45 Initiating treatment with checkpoint inhibitor monotherapy or combinations Antoni Ribas, Los Angeles, USA 12:45–13:20Starting treatment with kinase inhibitors or immunotherapy Grant McArthur, Melbourne, Australia 13:20–13:30Q & A session panel and concluding remarks program chair 15:30 –17:00 SATELLITE SYMPOSIUM VI Novartis (platinum sponsor) ROYAL BALLROOM A new era: Achieving personalized medicine in BRAF V600-mutant metastatic melanoma CHAIRPERSON: DIRK SCHADENDORF, ESSEN, GERMANY 15:30–15:40Welcome Dirk Schadendorf, Essen, Germany 15:40–16:00BRAF V600 mutated metastatic melanoma: Our current understanding of the disease Christoph Höller, Vienna, Austria 16:00–16:20Practicing individualized treatment in the clinic Paola Queirolo, Genova, Italy 16:20–16:40Onwards and upwards: A look to the future Caroline Robert, Paris, France 16:40-16:55Q & A with the faculty All 16:55-17:00Wrap up and close Dirk Schadendorf, Essen, Germany 15 For patients with advanced melanoma START WITH KEYTRUDA1 The first anti–PD-1 to demonstrate superior overall survival vs ipilimumab1 68% 1-year estimated overall survival rate vs 58% with ipilimumaba,b Kaplan-Meier curve for overall survival by treatment arm. HR (95% CI) vs ipilimumab KEYTRUDA 10 mg/kg* Q3W 0.69 (0.52–0.90) KEYTRUDA 10 mg/kg* Q2W 0.63 (0.47–0.83) Ipilimumab Risk reduction vs ipilimumab 31% 37% P value 0.00358 0.00052 KEYNOTE-006 study design: An open-label, multicenter, randomized, controlled Phase 3 trial that included patients with unresectable or metastatic melanoma who were naïve to ipilimumab and who had received no more than 1 prior systemic therapy. Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy. Patients were randomized (1:1:1) to receive KEYTRUDA at a dose of 10 mg/kg* every 2 (n=279) or 3 weeks (n=277) or ipilimumab (n=278). The primary efficacy outcome measures were overall survival (OS) and progression-free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria In Solid Tumors [RECIST 1.1]).1 In intent-to-treat population. b Median not reached. PD-1=programmed death receptor-1; Q3W=every 3 weeks; Q2W=every 2 weeks; HR=hazard ratio; CI=confidence interval. * The recommended dosage according to Prescribing Information is 2 mg/kg every 3 weeks. a KEYTRUDA is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic melanoma. KEYTRUDA® KEYTRUDA® 50 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung Wirkstoff: Pembrolizumab Zus.: 1 Durchstechfl. enth.: Arzneil. wirks. Bestandt.: 50 mg Pembrolizumab. Nach Rekonstitution enth. 1 ml Lsg. 25 mg Pembrolizumab. Sonst. Bestandt.: L-Histidin, L-Histidinhydrochlorid-Monohydrat, Sucrose, Polysorbat 80. Anw.: Als Monother. zur Behandl. d. fortgeschrittenen (nicht resezierbaren od. metastasierenden) Melanoms bei Erw. Gegenanz.: Überempf.-keit geg. d. Wirkstoff od. e. d. sonst. Bestandt. Stillzeit. Vorsicht bei: Schwerer Einschränk. d. Nierenfunkt.; moderater od. schwerer Einschränk. d. Leberfunkt (nur begrenzte Daten). Melanom d. Auges (limitierte Daten zu Sicherh. u. Wirksamk.). Kdr. u. Jugendl. < 18 J. (keine Daten). Behandl. nach Risikoabwägung (keine Daten) bei Pat. mit: HIV-, Hepatitis-B- od. Hepatitis-C-Infekt.; akt., system. Autoimmunerkrank.; Pneumonitis od. schwerer Überempf.-keit geg. e. and. monoklonalen Antikörper in d. Anamnese; laufender Ther. mit Immunsuppressiva; schweren immunvermittelten NW unter Ipilimumab in d. Anamnese (jegliche Grad 4 od. Grad 3 Toxizität), d. eine Kortikosteroid-Behandl. über mehr als 12 Wo. erforderte (mehr als 10 mg/Tag Prednison od. Äquivalent in entspr. Dosierung); aktiv. Infekt.-erkrank. Schwangersch. Nebenw.: Sehr häufig: Diarrhö; Übelk. Hautausschl. (einschl. erythemat., follikul., general., makulärer, makulo-papulöser, papulöser, juck., vesikul. Hautausschl.); Pruritus (einschl. Urtikaria, general. Pruritus). Arthralgie. Müdigk./Erschöpf. Häufig: Anämie; Thrombozytopenie. Hypophysitis (einschl. Hypophysenunterfunkt.); Hyperthyreose; Hypothyreose. Vermind. Appetit; Dehydrierung. Kopfschm.; Dysgeusie; periph. Neuropathie; Schwindel; Parästhesie. Trock. Augen. Vertigo. Hitzewall. Pneumonitis (einschl. interstit. Lungenerkrank.); Dyspnoe; Husten. Kolitis (einschl. mikroskop. Kolitis, Enterokolitis); Erbr.; Abdominalschm. (einschl. abdominaler Beschw., Oberbauch- u. Unterbauchschm.); Obstipat.; Mundtrockenh.; aufgeblähtes Abdomen. Schwere Hautreakt. (einschl. exfoliativ. Dermatitis, Erythema multiforme, exfoliativ. Hautausschl., SJS, Grad ≥ 3 Pruritus, Hautausschl., general. Hautausschl., makulo-papulöser Hautausschl.); Vitiligo (einschl. Hautdepigment.); Hauttrockenh.; Erythem; Ekzem; Hyperhidrose (einschl. Nachtschweiß); Hypopigment. d. Haut; Alopezie. Myalgie; Muskelschw.; muskuloskelett. Schm. (einschl. muskuloskelett. Beschw.); Schm. in d. Extremitäten; Rückenschm.; Arthritis; Muskelkrämpfe; muskuloskelett. Steifheit. Asthenie; Fieber; Schleimhautentzünd.; periph. Ödeme; grippeähnl. Erkrank.; Schüttelfrost. Erhöh. Werte von: AST; ALT; alkal. Phosphatase im Blut; Gewichtsabnahme. Infus.-bedingte Reakt. (einschl. Überempf.-keit geg. d. AM, anaphylakt. Reakt., Überempf.-keit, „Cytokine-Release-Syndrom“). Gelegentl.: Divertikulitis; Pneumonie; Konjunktivitis; Herpes zoster; Candida-Infekt.; Influenza; Harnwegsinfekt.; Herpes (simplex) im Mundbereich; Nasopharyngitis; Follikulitis. Tumorschm. Neutropenie; Lymphopenie; Leukopenie; Eosinophilie. Nebenniereninsuff.; Thyreoiditis (einschl. autoimmuner Thyreoiditis). Typ-I-Diabetes mellitus; Hyponatriämie; Hypokaliämie; Hyperglykämie; Hypophosphatämie; Hypalbuminämie; Hypertriglyzeridämie; Hypokalzämie; Hypomagnesiämie; Hypercholesterinämie; Hyperkalzämie; Hyperurikämie. Verwirrtheitszustand (einschl. Desorientier.); Schlaflosigk.; Ängstlichk.; vermind. Libido; Depress. Hypoästhesie; Lethargie; Neuralgie; periphere sensor. Neuropathie; Hypogeusie; Restless-Legs-Syndrom; Hypotonie; Gedächtnisstör.; Tremor; Gleichgewichtsstör.; Aufmerksamkeitsstör.; Hyperästhesie; Hypersomnie. Uveitis (einschl. Iritis u. Iridocyclitis); Augenschm.; Sehstör.; Juckreiz d. Augen; Verschwommensehen; erhöh. Tränensekret.; okul. Hyperämie; Augenreiz.; Verfärb. d. Wimpern; Photophobie; Mouches volantes. Perikarderguss; Palpitat. Hypotonie; Hitzegefühl/Flush; Raynaud-Syndrom. Pleuraschm.; Dysphonie; Giemen; verstopfte Nase; Schm. im Mundrachenraum; Hämoptoe; produkt. Husten; schmerzhafte Atmung; Epistaxis; Nasenlaufen; Niesen. Pankreatitis; Dysphagie; Schm. im Mund; gastroösophag. Refluxkrank.; Dyspepsie; Gastritis; Hämorrhoiden; Zahnerkrank.; Flatulenz.; Zahnfleischschm.; Stomatitis; Cheilitis. Hepatitis (einschl. autoimmune Hepatitis); Cholestase. Palmoplant. Erythrodysästhesie-Syndrom; Psoriasis; akneiforme Dermatitis; Dermatitis; Farbveränd. d. Haare; Papeln; photosensitive Hautreakt.; Hauterkrank.; Hautläsion; Hautgeschwülste; abnormes Haarwachstum; lichenoide Keratose; Hautverfärb.; Hyperpigment. d. Haut; Erythema nodosum; Pigmentstör.; Hautgeschwüre. Myositis (einschl. Myopathie u. Rhabdomyolyse); Steifheit d. Gelenke; Schwell. d. Gelenke; Polymyalgia rheumatica; Polyarthritis; Schm. im Kiefer; Knochenschm.; Flankenschm.; Synovitis; Nackenschm.; Muskelzuck. Nephritis (einschl. Autoimmunnephritis u. tubulointerstit. Nephritis); akute Niereninsuff.; Niereninsuff.; chron. Niereninsuff.; Pollakisurie; Dysurie. Unterleibsschm.; erektile Dysfunktion; Menorrhagie. General. Ödeme; Schm.; Schm. im Brustkorb; Entzünd.; Gangstör.; Beschw. im Brustkorb; Wärmeunverträglichk.; Unwohlsein; Ödeme; Gesichtsödem; Xerose; Hitzegefühl; Durst. Erhöh. Werte von: Kreatinphosphokinase im Blut; GGT; Amylase; Blutglukose; Kreatinin im Blut; Bilirubin im Blut; TSH im Blut; Trijodthyronin; Triglyzeriden im Blut; Cholesterin im Blut; freiem Thyroxin; Transaminasen; Kalzium im Blut; erniedr. Werte von: TSH im Blut; Thyroxin. Gewichtszunahme. Selten: Akrochordon; Neoplasmaschwell. Immunthrombozytopen. Purpura; hämolyt. Anämie; Panzytopenie. Autoimmunerkrank. Affekt. Stör.; Agitiertheit; Halluzinat.; Trance. Hirnödem; Enzephalopathie; Epilepsie; nichtinfekt. Meningitis; Myasthenie-Syndrom; Krämpfe; Dysarthrie; fokale Krampfanfälle; Synkope. Doppeltsehen; Erkrank. d. Auges; Erkrank. d. Augenlids; Makula-Degeneration; periorbit. Ödem; Photopsie. Lagerungsschwindel. Vorhofflimmern. Hypertonie; Lymphödem; Vaskulitis. Pleuraerguss; Kongestion d. Atemwege. Dünndarmperforation; Blutungen im oberen GIT; Oberbauchbeschw.; Glossitis; Zahndemineral. Akne; Kontaktdermatitis. Plant. Fasziitis; Arthropathie; Sehnenschm.; Sehnenentzünd.; Sehnenscheidenentzünd. Harninkont. Dysmenorrhö; Hämatospermie; genitaler Juckreiz; skrotales Erythem. Entzünd.-schm.; lokale Schwell.; lokal begrenztes Ödem; Reakt. an d. Infus.-stelle; Schwell. Autoantikörper-positiv; QT-Verlängerung im EKG; verläng. aktiv. part. Thromboplastinzeit; erniedr. Testosteronwerte im Blut; erhöh. Harnsäurewerte im Blut; erhöh. Werte von CRP; erhöh. Anzahl an Eosinophilen. Zusätzl.: diabet. Ketoazidose. Opt. Neuritis. Ther.-bedingte Antikörper. Warnhinw.: Zuverlässige Verhütungsmethode b. Frauen im gebährf. Alter bis 4 Mon. nach Behandl.-ende. Verschreibungspflichtig. Stand: 07/2015 Bitte lesen Sie vor Verordnung von KEYTRUDA® die Fachinformation! Pharmazeutischer Unternehmer: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU Vereinigtes Königreich Lokaler Ansprechpartner: MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540 Haar Reference: 1. Robert C, Schachter J, Long GV, et al, for the KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. 16 Copyright © 2016 MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540 Haar. www.msd.de. Alle Rechte vorbehalten. ONCO-1172474-0000 01/16 GENERAL INFORMATION Congress Venue Leonardo Royal Hotel Munich, Moosacher Straße 90, 80809 Munich Phone: +49 (0)89 2885380, E-Mail: [email protected] www.leonardo-hotels.com/Leonardo_Royal_Hotel_Munich Congress Date June 30th–July 1st, 2016 Registration and Information Desk The registration desk is situated at the ground floor of the Leonardo Royal Hotel to the left of the reception. Registration Desk Opening Hours Wednesday, June 29th, 2016 17:00–19:00 (early check-in) Thursday, June 30th, 2016 08:00–20:00 Friday, July 1st, 2016 07:00–20:00 Accomodation Individual hotel reservation: Please contact the congress hotel or one of the hotels nearby directly for your individual room bookings. MedConcept has reserved a limited number of rooms under the reference “European Post-Chicago Meeting 2016” in the following hotels: Leonardo Royal Hotel Munich**** Moosacher Str. 90, 80809 Munich Phone: +49 (0)89 62039779, Fax: +49 (0)89 62039717, E-Mail: [email protected] Rate per standard room and night: 159 Euro single and 180 Euro double, breakfast included Booking deadline: May 24th, 2016 Four Points By Sheraton München Olympiapark**** Helene-Meyer-Ring 12, 80809 Munich Phone: +49 (0)89 35751750, Fax: +49 (0)89 35751755, E-Mail: [email protected] Rate per standard room and night: 139 Euro single and 159 Euro double, breakfast included Booking deadline: May 29th, 2016 Distance to Leonardo Royal Hotel: 1 km All booking of rooms only according to availability! All rates include 19 % VAT! Call for Abstracts All those interested in presenting abstracts at the 6th European Post-Chicago Melanoma Meeting are invited to submit their work to the Program Committee for review. Selected abstracts will be chosen for an oral presentation during the Free Communications Sessions. The best poster on display will be awarded during the congress on July 1st at 10:25 with a poster award of 1.000 Euro. The acceptance of an abstract does not include the congress registration. Abstracts can be submitted online at www.melanomaglobal2016.org. Deadline Abstract Submission: May 1st, 2016 17 CME Credits An application for CME accreditation will be made. Cancellation Policy Cancellations must be received in writing by May 1st, 2016. No refunds will be granted after that date. To cancel a registration, please send an email to [email protected] and include “European Post-Chicago Melanoma Meeting 2016 Cancellation” in the subject line. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions (new ticket holder must come from the same institution) are possible and must be received in writing by June 19th, 2016. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to [email protected] and include “European Post-Chicago Melanoma Meeting 2016 Substitution” in the subject line. The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso. Exhibition A commercial exhibition will be held at the congress venue, close to the main rooms. Exhibition Opening Hours Thursday, June 30th, 2016 09:00–18:30 Friday, July 1st, 2016 07:30–18:30 Language and Translation The official language of the meeting will be English. Simultaneous translation will not be provided. Insurance The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance. Passport and Visa For most nationalities visas are not required for entering Germany. For further information about visa and passport please contact the German embassy in your country. If an invitation letter for visa purposes is required please contact MedConcept. Registration Please visit the congress website www.melanomaglobal2016.org for online registration or fill out the registration form on the last page of the program. Registration Fees Early registration till April 5th From April 6th till June 19th On site Full Delegates 300 Euro 400 Euro 500 Euro Doctors in training* and Eastern European Countries 200 Euro 250 Euro 300 Euro Day Ticket 150 Euro 200 Euro 250 Euro *Please forward appropriate documentary evidence via mail, email or fax to the congress office: MedConcept GmbH, Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany, [email protected], Fax: +49 (0)3342 42689-30 After June 19th all registrations have to be on-site at the meeting venue. 18 Important Dates Early Registration Fee: till April 5th, 2016 Deadline Abstract Submission: May 1st, 2016 Notification of Acceptance of Abstracts: May 16th, 2016 Closing of Pre-Registration: June 19th, 2016 Congress Organization Gesellschaft für medizinische Projekte mbH Friedenstraße 58 · 15366 Neuenhagen bei Berlin, Germany [email protected] · www.medconcept.org Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40 On-site cellphone numbers: Mirja Christ: +49 (0)176 62890497 Alexandra Hansen: +49 (0)151 17161221 Christopher Huhn: +49 (0)151 17161223 www.melanomaglobal2016.org 19 SPONSORS PLATINUM 120,000 Euro Platinum Sponsorship 120,750 Euro Platinum Sponsorship incl. Meeting Room 120,000 Euro Platinum Sponsorship BRONZE FURTHER SPONSORS Delcath Systems Limited medac GmbH Philogen S.p.A. 20 120,000 Euro Platinum Sponsorship REGISTRATION FORM June 30th–July 1st, 2016 · 6 th European Post-Chicago Melanoma / Skin Cancer Meeting 2016 Results and Interpretations of ASCO Presentations 2016: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer First Name: Last Name: Professional Title: Gender: Male Degree: MD PhD RN PA-C Other Female Speciality: Institution: Address: City: State: Zip Code: Daytime Telephone: Fax: Country: E-Mail: Fees (VAT included) Early registration till April 5th From April 6th till June 19th On site Full Delegates 300 Euro 400 Euro 500 Euro Doctors in training* and Eastern European Countries 200 Euro 250 Euro 300 Euro Day Ticket 150 Euro 200 Euro 250 Euro June 30th July 1st *Please forward appropriate documentary evidence via mail, email or fax to the congress office: MedConcept GmbH, Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany, [email protected], Fax: +49 (0)3342 42689-40 Total Amount: Euro Payment Method Cash (Euro): Credit Card: MasterCard Visa American Express Credit Card Number: Expiration Date: Security Code CCV: (MC/Visa – 3 digits on back, AMEX – 4 digits on front) Cardholder Name: Signature: Congress Organization Gesellschaft für medizinische Projekte mbH Friedenstraße 58 · 15366 Neuenhagen bei Berlin [email protected] · www.medconcept.org Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40 21 22 NOTES 23 NOTES STRONGER NEU: ® LIC COTEL ion inat io in Komb af® or mi t Zelb TOGETHER Bei BRAF-mutiertem fortgeschrittenem Melanom: Überzeugende Langzeitwirkung1,2 1. McArthur GA et al. Eur J Cancer 2015; 51: S720–S723. 2. Atkinson V et al. SMR 2015. Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Sie können dabei helfen, indem Sie jede auftretende Nebenwirkung melden. Cotellic® 20 mg Filmtabletten. Wirkstoff: Cobimetinib. Zusammensetzung: Jede Filmtablette enthält Cobimetinibhemifumarat, entsprechend 20 mg Cobimetinib. Sonstige Bestandteile: Tablettenkern: Lactose-Monohydrat , Mikrokristalline Cellulose, Croscarmellose-Natrium, Magnesiumstearat; Tablettenüberzug: Poly(vinylalkohol), Titandioxid, Macrogol und Talkum. Anwendungsgebiet: Cotellic wird in Kombination mit Vemurafenib angewendet zur Behandlung bei erwachsenen Patienten mit nicht resezierbarem oder metastasiertem Melanom mit einer BRAF-V600-Mutation. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff oder sonstige Bestandteile. Nebenwirkungen: Sehr häufig: Blutarmut, seröse Retinopathie, Bluthochdruck, Blutungen, Übelkeit, Erbrechen, Lichtempfindlichkeit, makulopapulöser Ausschlag, Akne-ähnlicher Ausschlag, Hyperkeratose, Fieber, erhöhte Leberenzymwerte, Anstieg der CPK. Häufig: kutanes Basalzellkarzinom, Plattenepithelkarzinom, Keratoakanthom, Dehydration, Hypophosphatämie, Hyponatriämie, Hyperglykämie, Pneumonitis, Schüttelfrost, verminderte Auswurffraktion, erhöhter Bilirubinwert im Blut. Warnhinweise: Bevor mit der Anwendung von Cotellic in Kombination mit Vemurafenib begonnen wird, muss ein durch einen validierten Test bestätigter BRAF-V600-Mutation-pos. Tumorstatus vorliegen. Bei Problemen mit den Augen, dem Herz oder der Leber vor der Einnahme den behandelnden Arzt konsultieren. Bei Durchfall umgehend den behandelnden Arzt konsultieren. Arzneimittel für Kinder unzugänglich aufbewahren. Enthält Lactose. Dosierung: Die empfohlene Dosis von Cotellic beträgt einmal täglich 3 Tabletten (insgesamt 60 mg). 21-tägiger Behandlungszyklus gefolgt von 7-tägiger Behandlungspause. Verschreibungspflichtig. Hinweise der Fachinformation beachten. Pharmazeutischer Unternehmer: Roche Registration Limited, Welwyn Garden City, Vereinigtes Königreich. Weitere Informationen auf Anfrage erhältlich. Vertreter in Deutschland: Roche Pharma AG, 79630 Grenzach-Wyhlen. Stand der Information: Dezember 2015 24 Erfahren Sie mehr unter www.cotellic.de LAYOUT UND DRUCK: MEDIASERVICE GMBH DRUCK UND KOMMUNIKATION FOTOS: TITELBILD: VISUALSUNLIMITED/DOC-STOCK · S4/5 ISTOCKPHOTO/SBORISOV, MANFREDXY, XYNO MÜNCHEN (2) · S6/7 PIXELIO.DE/ PETRA DIRSCHERL, GERHARD PRANTL, FLICKR ST. DAMENKAPELLE S8/9 ISTOCKPHOTO/SEEWHATMITCHSEE, ALEXM156, PIXELIO.DE/ALEXANDER HAUK – BAYERN.NACHRICHTEN.DE · S10 ISTOCKPHOTO/SVEN PETER, PIXELIO.DE/HARTMUT910
